Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Feb 19:18:435-454.
doi: 10.2147/PPA.S446106. eCollection 2024.

Patient and Healthcare Professional Preferences for Prescription Weight Loss Medications in Australia: Two Discrete Choice Experiments

Simon Fifer  1 , Brittany Keen  1 , Anna Porter  2
Affiliations

Patient and Healthcare Professional Preferences for Prescription Weight Loss Medications in Australia: Two Discrete Choice Experiments

Simon Fifer et al. Patient Prefer Adherence. .

Abstract

Purpose: Overweight and obesity are common in Australia and among the leading risk factors for ill health. Maintained weight loss of >5-10% can prevent and reduce the risk of obesity-related comorbidities. Prescription weight loss medications plus lifestyle interventions can result in additional weight loss compared with lifestyle interventions alone, but these medications are under-prescribed in Australia. Our aim was to develop a greater understanding of the treatment preferences of people with overweight or obesity and the healthcare practitioners (HCPs) who treat them.

Participants and methods: An online survey of Australian adults with overweight or obesity and treating HCPs was conducted in 2020. A discrete choice experiment (DCE) approach was used to determine what is most important to people when evaluating oral and injectable prescription weight loss medications. Participants were asked to choose between three hypothetical treatment alternatives: "Oral pill"; "Subcutaneous injection pen (replaceable needle)"; "Disposable subcutaneous injection pen (hidden needle)"; and an opt-out option ("None of these").

Results: The online survey and DCE were completed by 193 patients and 104 HCPs. For both patients and HCPs, all treatment alternatives (oral, replaceable injection and disposable injection) were preferred over the opt-out. Gastrointestinal side effects, followed by success rate, percentage body weight lost, and cost were the most important attributes to patients. For HCPs, percentage body weight loss was the most important treatment attribute, followed by success rate, gastrointestinal side effects and cost. While most patients reported relatively low needle fear, physicians reported relatively high perceived patient needle fear.

Conclusion: Clinician-patient discussions about treatments for weight loss should cover the option of prescription weight loss medications, including injectable medications, which patients may be less apprehensive about than physicians believe. Treatments with a high success rate and low or manageable risk of gastrointestinal side effects may be preferred over alternatives.

Keywords: discrete choice experiment; obesity; overweight; shared decision-making; treatment; treatment preferences.

PubMed Disclaimer

Conflict of interest statement

SF and BK are employed by CaPPRe. CaPPRe has consulted to Abbvie, Amgen, AstraZeneca, Celgene, CSL Behring, Edwards, GSK, Ipsen, Janssen, Novo Nordisk, Roche, Sanofi, Shire and UCB, outside of the submitted work. AP is an employee of Novo Nordisk Australia. The authors report no other conflicts of interest in this work.

Figures

Figure 1
Figure 1
Example of DCE choice task (wording differed slightly for patients and HCPs).
Figure 2
Figure 2
Reported barriers to taking/prescribing weight loss medications.
Figure 3
Figure 3
Perceptions of patient needle fear, as reported by patients and healthcare professionals.
Figure 4
Figure 4
Relative importance of treatment attributes influencing patient choices in the DCE.
Figure 5
Figure 5
Relative importance of treatment attributes influencing healthcare provider (HCP) choice in the DCE.
See this image and copyright information in PMC

Similar articles

See all similar articles

References

    1. AIHW. Impact of Overweight and Obesity as a Risk Factor for Chronic Conditions: Australian Burden of Disease Study. Canberra: AIHW; 2017.
    1. World Health Organization. Obesity: preventing and managing the global epidemic. Report of a WHO consultation. World Health Organization Technical Report Series. 2000;i–xii, 1–253. - PubMed
    1. Jensen MD, Ryan DH, Apovian CM, et al. 2013 AHA/ACC/TOS guideline for the management of overweight and obesity in adults: a report of the American College of Cardiology/American Heart Association task force on practice guidelines and the obesity society. Circulation. 2014;129(25 Suppl 2):S102–S138. doi:10.1161/01.cir.0000437739.71477.ee - DOI - PMC - PubMed
    1. World Health Organization. Obesity and overweight; 2021. Available from: https://www.who.int/news-room/fact-sheets/detail/obesity-and-overweight. Accessed November, 2021.
    1. Australian Institute of Health and Welfare (AIHW). Overweight and Obesity in Australia: A Birth Cohort Analysis. Canberra: AIHW; 2017.